The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria, assessed significant new findings for local and systemic therapies for early breast cancer with a focus on the evaluation of multimodal treatment options. The emergence of more effective, innovative agents in both the preoperative (primary or neoadjuvant) and post-operative (adjuvant) settings has underscored the pivotal role of a multidisciplinary approach in treatment decision making, particularly when selecting systemic therapy for an individual patient. The importance of multidisciplinary discussions regarding the clinical benefits of interventions was explicitly emphasized by the consensus panel as an integral part of developing an optimal treatment plan with the ‘right’ degree of intensity and duration. The panelists focused on controversies surrounding the management of common ductal/no special type and lobular breast cancer histology, which account for the vast majority of breast tumors. The expert opinion of the panelists was based on interpretations of available data, as well as current practices in their professional environments, personal and socioeconomic factors affecting patients, and cognizant of varying reimbursement and accessibility constraints around the world. The panelists strongly advocated patient participation in well-designed clinical studies whenever feasible. With these considerations in mind, the St Gallen Consensus Conference aims to offer guidance to clinicians regarding appropriate treatments for early-stage breast cancer and assist in balancing the realistic trade-offs between treatment benefit and toxicity, enabling patients and clinicians to make well-informed choices through a shared decision-making process.

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 / Curigliano, G.; Burstein, H. J.; Gnant, M.; Loibl, S.; Cameron, D.; Regan, M. M.; Denkert, C.; Poortmans, P.; Weber, W. P.; Thurlimann, B.; Aebi, S.; Al-Foheidi, M.; Andre, F.; Anikusko, M.; Badwe, R.; Barrio, A. V.; Barrios, C.; Bergh, J.; Bonnefoi, H.; Bretel Morales, D.; Brucker, S.; Caldas, C.; Cardoso, F.; Cardoso, M. J.; Carey, L.; Chia, S.; Coles, C.; Cortes, J.; de Boniface, J.; Delaloge, S.; Demichele, A.; Fastner, G.; Fitzal, F.; Francis, P.; Gamal, H.; Gentilini, O.; Gradishar, W.; Gulluoglu, B.; Harbeck, N.; Heil, J.; Huang, C. -S. H.; Huober, J.; Jiang, Z.; Kaidar-Person, O.; Kok, M.; Lee, E. -S.; Loi, S.; Martin, M.; Meattini, I.; Morrow, M.; Partridge, A.; Penault-Llorca, F.; Piccart, M.; Pierce, L.; Regan, M.; Reis-Filho, J.; Rubio, I.; Rugo, H.; Rutgers, E.; Saura, C.; Senkus, E.; Shao, Z.; Singer, C.; Spanic, T.; Thuerlimann, B.; Toi, M.; Tolaney, S.; Turner, N.; Tutt, A.; Vrancken Peeters, M. -J.; Watanabe, T.; Weber, W.; Wildiers, H.; Xu, B.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 34:11(2023), pp. 970-986. [10.1016/j.annonc.2023.08.017]

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Gentilini O.;
2023-01-01

Abstract

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria, assessed significant new findings for local and systemic therapies for early breast cancer with a focus on the evaluation of multimodal treatment options. The emergence of more effective, innovative agents in both the preoperative (primary or neoadjuvant) and post-operative (adjuvant) settings has underscored the pivotal role of a multidisciplinary approach in treatment decision making, particularly when selecting systemic therapy for an individual patient. The importance of multidisciplinary discussions regarding the clinical benefits of interventions was explicitly emphasized by the consensus panel as an integral part of developing an optimal treatment plan with the ‘right’ degree of intensity and duration. The panelists focused on controversies surrounding the management of common ductal/no special type and lobular breast cancer histology, which account for the vast majority of breast tumors. The expert opinion of the panelists was based on interpretations of available data, as well as current practices in their professional environments, personal and socioeconomic factors affecting patients, and cognizant of varying reimbursement and accessibility constraints around the world. The panelists strongly advocated patient participation in well-designed clinical studies whenever feasible. With these considerations in mind, the St Gallen Consensus Conference aims to offer guidance to clinicians regarding appropriate treatments for early-stage breast cancer and assist in balancing the realistic trade-offs between treatment benefit and toxicity, enabling patients and clinicians to make well-informed choices through a shared decision-making process.
2023
early breast cancer
ER-positive breast cancer surgery
HER2-positive breast cancer
radiation therapy
triple-negative breast cancer
File in questo prodotto:
File Dimensione Formato  
2023Understanding breast cancer complexity to improve patient outcomes.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 620.77 kB
Formato Adobe PDF
620.77 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/159796
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 53
social impact